ME(Delisted)
23andMe·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 0
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ME
23andme Holding Co.
A genetics-led consumer healthcare and therapeutics company
349 Oyster Point Boulevard, South San Francisco, California 94080
--
23andMe Holding Co., incorporated in Delaware on February 19, 2020, is a leading consumer genetics and research company. Its mission is to help people acquire, understand and benefit from the human genome. 23andMe is the first to have direct access to genetic information and is the only genetic health risk reporting company with multiple FDA authorizations. 23andMe has created the world's largest crowdsourcing platform for genetic research, with 80 percent of its customers choosing to participate.
Company Financials
EPS
ME has released its 2025 Q3 earnings. EPS was reported at -1.02, versus the expected -0.16, missing expectations. The chart below visualizes how ME has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ME has released its 2025 Q3 earnings report, with revenue of 60.26M, reflecting a YoY change of 34.67%, and net profit of -53.03M, showing a YoY change of 80.92%. The Sankey diagram below clearly presents ME's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
